http://orcid.org/0000-0002-4971-3576
References
- Emile J-F, Abla O, Fraitag S, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016;127(22):2672–2681.
- Hervier B, Haroche J, Arnaud L, et al. Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation. Blood. 2014;124(7):1119–1126.
- Pineles SL, Liu GT, Acebes X, et al. Presence of Erdheim-Chester disease and Langerhans cell histiocytosis in the same patient: a report of 2 cases. J. Neuro-Ophthalmol. 2011;31(3):217–223.
- Tsai J-W, Tsou J-H, Hung L-Y, et al. Combined Erdheim-Chester disease and Langerhans cell histiocytosis of skin are both monoclonal: a rare case with human androgen-receptor gene analysis. J Am Acad Dermatol. 2010;63(2):284–291.
- Furmanczyk PS, Bruckner JD, Gillespy T, et al. An unusual case of Erdheim–Chester disease with features of Langerhans cell histiocytosis. Skeletal Radiol. 2007;36(9):885–889.
- Yin J, Zhang F, Zhang H, et al. Hand-Schuller-Christian disease and Erdheim-Chester disease: coexistence and discrepancy. Oncologist. 2013;18(1):19–24.
- Strehl JD, Stachel KD, Hartmann A, et al. Juvenile xanthogranuloma developing after treatment of Langerhans cell histiocytosis: case report and literature review. Int J Clin Exp Pathol. 2012;5(7):720–725.
- Reid CD, Stackpoole A, Meager A, et al. Interactions of tumor necrosis factor with granulocyte-macrophage colony-stimulating factor and other cytokines in the regulation of dendritic cell growth in vitro from early bipotent CD34+ progenitors in human bone marrow. J Immunol. 1992;149(8):2681–2688.
- Fogg DK, Sibon C, Miled C, et al. A clonogenic bone marrow progenitor specific for macrophages and dendritic cells. Science. 2006;311(5757):83–87.
- Diamond EL, Subbiah V, Lockhart AC, et al. Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, Phase 2, Open-label VE-BASKET Study . JAMA Oncol. 2018;4(3):384.
- Allen CE, Ladisch S, McClain KL. How I treat Langerhans cell histiocytosis. Blood. 2015;126(1):26–35.
- Weitzman S, Braier J, Donadieu J, et al. Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH) results of the LCH-S-98 protocol of the histiocyte Society. Pediatr Blood Cancer. 2009;53(7):1271–1276.
- Simko SJ, Tran HD, Jones J, et al. Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease. Pediatr Blood Cancer. 2014;61(3):479–487.
- Abraham A, Alsultan A, Jeng M, et al. Clofarabine salvage therapy for refractory high-risk langerhans cell histiocytosis. Pediatr Blood Cancer.. 2013;60(6):E19–E22.
- Foss-Skiftesvik J, Scheie D, Klausen C, et al. Rare childhood hybrid histiocytosis of the central nervous system – diagnosed by stereotactic brain biopsy with marked treatment response to clofarabine. Childs Nerv Syst. 2018;34(11):2321–2324.